LifeSci Capital analyst Adam Evertts PhD reiterated a Buy rating on Odonate Therapeutics (NASDAQ:ODT) Llc on Monday, setting a price target of $56, which is approximately 66.96% above the present share price of $33.54.
Evertts PhD expects Odonate Therapeutics Llc to post earnings per share (EPS) of -$0.99 for the third quarter of 2020.
The current consensus among 2 TipRanks analysts is for a Hold rating of shares in Odonate Therapeutics, with an average price target of $56.
The analysts price targets range from a high of $56 to a low of $56.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$30.82 million. The company's market cap is $1.08 billion.
According to TipRanks.com, LifeSci Capital analyst Adam Evertts PhD is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 6.7% and a 53.85% success rate.
Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.